Ethyl hydrogen (4-{[4-({2-(diethylcarbamoyl)-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate → ethyl hydrogen (4-{[4-({6-[3-cyano-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)pyridin-3-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate

Participants

Reaction Steps

Prepared analogously to Compound 3A using diethyl (4-{[4-({6-[3-cyano-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)pyridin-3-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate (Compound 52B, 259 mg, 0.361 mmol) to afford 250 mg of the title compound (100%). 1H NMR (400 MHz, CD3OD) δ 9.09 (d, J=7.8 Hz, 1H), 8.88 (br. s., 1H), 8.30 (s, 1H), 7.86 (d, J=9.1 Hz, 1H), 7.51 (br. s., 1H), 7.11 (s, 1H), 6.97 (d, J=7.8 Hz, 1H), 4.39 (t, J=6.8 Hz, 2H), 3.83-3.94 (m, 5H), 3.62 (t, J=5.9 Hz, 2H), 3.00-3.08 (m, 2H), 2.97 (s, 3H), 2.10-2.20 (m, 2H), 1.14 (t, J=7.1 Hz, 3H). MS (ESI): m/z=690.49 [M+H]+. UPLC: tR=1.26 min (UPLC-TOF: polar—2 min).

Provenance & Evidence